| Recruiting | A Clinical Trial of PepZinGI® for Acute Heartburn Relief and Sleep Outcomes NCT07379645 | NutriScience Innovations, LLC | N/A |
| Recruiting | A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring NCT06660342 | Phathom Pharmaceuticals, Inc. | — |
| Completed | Observationa Study is a Prospective and Multi-institutional Observational Study. NCT06952855 | Jeil Pharmaceutical Co., Ltd. | — |
| Completed | A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 2 NCT06391177 | Phathom Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Rio NCT06098742 | Valenta Pharm JSC | N/A |
| Completed | A First-in-Human Study to Learn How Well a Bi-Layer Calcium Carbonate Antacid Tablet Works Compared to a Stand NCT06293326 | Bayer | Phase 1 |
| Recruiting | A Study of Breath Testing for Small Intestinal Bacterial Overgrowth NCT05976165 | Mayo Clinic | N/A |
| Completed | The Effect of the LEFT Smartwatch App as Sleep Positional Therapy for Nocturnal Gastroesophageal Reflux Sympto NCT06075082 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | N/A |
| Completed | Smartphone App-assisted PPI NCT06094062 | University Hospital, Basel, Switzerland | N/A |
| Unknown | Prevalence of Fuctional Heartburn in Patients With IBS . NCT05901740 | Assiut University | — |
| Active Not Recruiting | Primary carE PPi dEprescRibing Trial NCT05629143 | Universitaire Ziekenhuizen KU Leuven | Phase 4 |
| Completed | Tolerability Study of Panosyl-Isomaltooligosaccharides (PIMO) and a Placebo in Subjects With Heartburn NCT05363618 | Microbiome Health Sciences | N/A |
| Completed | A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Parti NCT05195528 | Phathom Pharmaceuticals, Inc. | Phase 3 |
| Completed | Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg Chewable Tablets and Riopan 8 NCT06552624 | Valenta Pharm JSC | N/A |
| Completed | A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic NCT04799158 | Phathom Pharmaceuticals, Inc. | Phase 2 |
| Completed | Implementation of a Minor Ailment Service in Community Pharmacy Practice NCT05247333 | Universidad de Granada | N/A |
| Completed | Remote Guided Caffeine Reduction NCT04560595 | Johns Hopkins University | N/A |
| Unknown | Study of Dietary Patterns and Food Diversity in Russian GERD Patients NCT04252144 | Russian Academy of Medical Sciences | N/A |
| Completed | Upset Stomach Relief for Mild and Moderate Indigestion and Heartburn NCT04153552 | Hawthorne Effect Inc. | N/A |
| Completed | Fermented Soy and Heartburn Symptom Relief NCT03867591 | University of Florida | N/A |
| Completed | Mipolixin® Compared to Poliprotect® in Moderate Functional Dyspepsia and Heartburn. NCT03531372 | Aboca Spa Societa' Agricola | N/A |
| Completed | Bile Reflux Gastropathy: Prevalence and Risk Factors After Therapeutic Biliary Interventions NCT05131802 | Zagazig University | — |
| Completed | Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients NCT02873689 | Takeda | Phase 3 |
| Completed | Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhib NCT02708355 | Pfizer | Phase 4 |
| Unknown | Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturba NCT02277886 | Chang Gung Memorial Hospital | Phase 4 |
| Unknown | Efficacy Study of Articaine Lozenge to Enhance the Procedural Compliance of the Adults Undergoing Gastroduoden NCT02105090 | Helsinki University Central Hospital | Phase 4 |
| Completed | Symptom Control Satisfaction With Proton Pump Inhibitor Regimen NCT02623816 | MetroHealth Medical Center | Phase 4 |
| Completed | Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets NCT02096458 | Takeda | Phase 1 |
| Completed | Response to Supplement and Placebo in GERD NCT01915173 | Beth Israel Deaconess Medical Center | N/A |
| Recruiting | Domperidone in Treating Patients With Gastrointestinal Disorders NCT01696734 | M.D. Anderson Cancer Center | Phase 3 |
| Completed | Comparison of Two Omeprazole-Containing Products for Relief of Frequent Heartburn (MK-0764A-036) NCT01587885 | Bayer | Phase 4 |
| Completed | Efficacy of Esomeprazole in Patients With Frequent Heartburn NCT01370525 | AstraZeneca | Phase 3 |
| Completed | Efficacy of Esomeprazole in Patients With Frequent Heartburn NCT01370538 | AstraZeneca | Phase 3 |
| Terminated | Rubber Band Ligation and Mucosectomy for Gastroesophageal Reflux Disease (GERD) NCT01199679 | Cook Group Incorporated | N/A |
| Completed | A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants NCT01337804 | Bayer | Phase 1 |
| Completed | To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Ra NCT01249651 | AstraZeneca | Phase 4 |
| Completed | Efficacy and Safety of Sodium Alginate Oral Suspension to Treat Non-erosive Gastro-esophageal Reflux Disease NCT01338077 | Chang Gung Memorial Hospital | Phase 3 |
| Completed | Assessment of Gastro-esophageal Reflux Using Endo-Flip vs Bravo NCT00481949 | Guy's and St Thomas' NHS Foundation Trust | — |
| Completed | Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump In NCT01149395 | University of North Carolina, Chapel Hill | Phase 1 |
| Unknown | Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe E NCT01129713 | Effexus Pharmaceutical | Phase 1 / Phase 2 |
| Completed | Do Acid Sensing Ion Channels Contribute to Heartburn? NCT01095133 | University of North Carolina, Chapel Hill | Phase 1 |
| Completed | Proof of Concept Study Efficacy of an Antacid/Lansoprazole Combination for Relief of Heartburn NCT01037452 | Novartis | Phase 2 |
| Completed | Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Part NCT01005251 | AstraZeneca | Phase 2 |
| Completed | Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD) NCT00842387 | AstraZeneca | — |
| Completed | Confocal Laser Microscopy in Non Erosive Reflux Disease NCT00588939 | Mayo Clinic | — |
| Completed | Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) NCT00703534 | AstraZeneca | Phase 2 |
| Completed | A Study to Assess the Bioequivalence of Famotidine/Antacid Combination Tablets Compared to Famotidine/Antacid NCT00944671 | Johnson & Johnson Consumer and Personal Products Worldwide | Phase 1 |
| Terminated | What is the Predictive Value of the Reflux Impact Scale NCT00536328 | AstraZeneca | — |
| Completed | Efficacy and Safety of Itopride vs Placebo in Heartburn NCT00382577 | Forest Laboratories | Phase 3 |
| Completed | Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD) NCT00373334 | Braintree Laboratories | Phase 3 |
| Completed | A Study to Assess the Bioequivalence of Famotidine Chewable Tablets and Film-Coated Tablets (0208-144) NCT00945750 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn NCT00390390 | Novartis | Phase 3 |
| Completed | Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn NCT00389948 | Novartis | Phase 3 |
| Completed | Esomeprazole and Gastric Emptying of Beer NCT00472550 | Heidelberg University | Phase 4 |
| Completed | Esomeprazole And Symptomatic Response In Patients With Or Without An Elevated Risk For Non-Steroidal Anti-Infl NCT00524329 | AstraZeneca | — |
| Completed | E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers NCT00236197 | Eisai Inc. | Phase 3 |
| Completed | E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers NCT00236184 | Eisai Inc. | Phase 3 |
| Completed | HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease NCT00243724 | AstraZeneca | Phase 3 |
| Completed | The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and NCT00171457 | Novartis | Phase 3 |
| Completed | Acid-Associated Heartburn Symptoms and Dose of Esomeprazole NCT00206024 | AstraZeneca | Phase 4 |
| Completed | Open Label Study Evaluating Different Dosing Regimens of Rabeprazole in Gastro-esophageal Reflux Disease (GERD NCT00553449 | Janssen-Ortho Inc., Canada | Phase 3 |
| Completed | A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of On NCT00625274 | AstraZeneca | Phase 4 |
| Completed | Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule NCT00579410 | VA Office of Research and Development | — |
| Completed | Questionnaire to Assess Gastrointestinal Symptoms of Oral Iron. NCT02146053 | Medical Research Council | EARLY_Phase 1 |
| Completed | Placebo Controlled Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single NCT01928888 | Bayer | Phase 4 |
| Completed | A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD) NCT00216489 | Janssen Cilag Pharmaceutica S.A.C.I., Greece | Phase 4 |
| Completed | Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Contro NCT00637845 | AstraZeneca | Phase 4 |
| Completed | A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosiv NCT00236392 | Janssen Pharmaceutica N.V., Belgium | Phase 3 |
| Unknown | A Comparison of Factors of Symptoms Generation and Evaluation of Role of Biofeedback in Patients With Differen NCT00471796 | Assaf-Harofeh Medical Center | N/A |